Introduction {#S1}
============

Tumor necrosis factor (TNF) is a pleiotropic cytokine involved in regulating diverse functions, including cell growth modulation, viral replication, septic shock, tumorigenesis, inflammation, and autoimmunity ([@B1], [@B2]). These functions hinge upon the binding of TNF to two distinct membrane receptors on target cells: TNF receptor (TNFR) 1and TNFR2. TNFR1 is expressed universally on almost all cell types, whereas TNFR2 is restricted to immune cells ([@B2]--[@B6]) and some tumor cells ([@B7]--[@B13]). Since TNFR1 and TNFR2 were identified ([@B14]), multiple studies have been carried out to characterize their structures and functions. While TNFR1 has been extensively characterized, the biological functions of TNFR2 have remained elusive ([@B15]). There is mounting evidence to suggest that TNFR2 is expressed on and has critical roles in immune cells, including CD4^+^ regulatory T cells (Tregs) ([@B16]), CD4^+^ effector T cells (Teffs) ([@B4]), CD8^+^ Tregs ([@B17]), and CD8^+^ Teffs ([@B18]). This implies that TNFR2 is involved in various T cell-mediated immune responses. TNFR2 expressed on CD4^+^ T cells has been studied in depth with many studies indicating that TNFR2 mediates the stimulatory activity of TNF on CD4^+^ Treg cells, resulting in their phenotypic stability, proliferation, and activation ([@B3], [@B19]--[@B22]). Furthermore, TNFR2 can be used to identify the maximally suppressive subset of CD4^+^ Tregs ([@B20]). However, studies on TNFR2 expression on CD8^+^ T cells are relatively deficient. Several studies have identified TNFR2 as a potent costimulatory molecule on CD8^+^ T cells required to sustain cell survival and protect from apoptosis, while TNFR2 expressing CD8^+^Foxp3^+^ Tregs exhibited highly suppressive activity ([@B17], [@B23], [@B24]).

The restricted distribution of TNFR2 has identified it as a potential target for immunotherapy. Targeting TNFR2 for cancer immunotherapy has seen remarkable success. Treatment of OVVAR3, an ovarian cancer cell line with surface expression of TNFR2, with a TNFR2 antagonist induced significant tumor cell death. Furthermore, the TNFR2 antagonist preferentially suppressed the activity of tumor-associated CD4^+^ Treg cells, but had little inhibitory effects on peripheral CD4^+^ Treg cells or cells from healthy donors ([@B25]). This result indicates that patients treated with a TNFR2 antagonist can maintain immunological homeostasis and mitigate the collateral damage to healthy tissues ([@B20], [@B25]). While the potential effects of TNFR2 antagonists on tumors have been documented, major questions remain unanswered, including how much the effects of therapeutically targeting TNFR2 *in vivo* are directly related to modulating T cell activity. Better knowledge of the fundamental biological processes, such as signaling pathway activation and the molecular mechanism underlying the T cell response to TNFR2 stimulation, especially in Treg cells, may help design safer and more effective targeted therapeutics. As TNFR2 expression on CD4^+^ T cells has been documented in detail, in this review, we mainly summarize and discuss the biological effects of TNFR2 expression on CD8^+^Foxp3^+^ Tregs and CD8^+^ Teffs.

TNFR2 Expressed on CD8^+^ Tregs {#S2}
===============================

The suppressive effects of CD8^+^ Tregs on normal and pathologic immune responses are well described (Figure [1](#F1){ref-type="fig"}) ([@B26]--[@B28]). Previous study demonstrated that human CD8^+^CD25^+^ Tregs share many features with CD4^+^CD25^+^ Tregs in the thymus, such as phenotype, function, and mechanisms of action ([@B23]). Increasing evidence suggests that TNFR2 is a significant biomarker for highly potent suppressive Tregs, because TNFR2 promotes the activation, expansion, and survival of CD4^+^ Tregs by mediating the effect of TNF ([@B29]). However, most studies on TNFR2 expression on Tregs have focused on the CD4^+^ Tregs population, rather than CD8^+^ Tregs. Current results suggest that TNFR2 might also be a critical suppressive maker of the functional CD8^+^Foxp3^+^ Tregs. However, CD8^+^ Tregs are not the CD8^+^ counterpart of CD4^+^ Tregs. There are multiple subsets of CD8^+^ Tregs reported in both humans and mice ([@B30]), such as CD8^+^CD122^+^ Tregs ([@B31]), CD8^+^CD28^−^ Tregs ([@B32], [@B33]), and CD8^+^CD103^+^ Tregs ([@B34], [@B35]). Unfortunately, the published studies on TNFR2 expression on CD8^+^Tregs all focused on CD8^+^Foxp3^+^ Tregs. As a consequence, we can only summarize the biological effects of TNFR2 expressed on CD8^+^Foxp3^+^ Tregs.

![Tumor necrosis factor (TNF) receptor type II (TNFR2) acts as a suppressive marker for CD8^+^ regulatory T (Tregs) cells. The TNF/TNFR2 interaction, as well as TNFR2 and CD28 agonists, could promote the induction of Foxp3 in the presence of anti-CD3. Additionally, the TNF/TNFR2 interaction could also upregulate CD25 and PD-L1, the negative molecules on the surface of CD8^+^ Tregs, to mediate a contact-dependent inhibition to CD4^+^ and CD8^+^ effector T cells, cooperation with other negative molecules on the surface of CD8^+^ Tregs, such as CTLA-4.](fimmu-09-00583-g001){#F1}

TNFR2 Is a Better Functional Treg Cell Marker Than CD25 for CD8^+^Foxp3^+^ Tregs {#S2-1}
--------------------------------------------------------------------------------

CD8^+^Foxp3^+^ Tregs can be generated *in vitro* with anti-CD3 antibodies ([@B17], [@B36], [@B37]) or anti-CD3/28 beads ([@B24]). These cells expressed CD25, Foxp3, TNFR2, and the negative co-stimulatory receptors CTLA-4, PD-1, PDL-1, and Tim-3 ([@B24]). When CD8^+^ T cells were isolated from peripheral blood mononuclear cells (PBMCs) from healthy donors and cultured with anti-CD3 mAb for 5 days, the TNFR2^+^CD25^+^ cells were identified as the main subset that expressed Foxp3 ([@B17]). Similarly, human CD25 and TNFR2-coexpressing CD4^+^ Tregs were identified as a potent subpopulation of Tregs ([@B22], [@B38]--[@B40]). Interestingly, when these CD8^+^Tregs were sorted into four subsets, CD25^+^TNFR2^+^, CD25^+^TNFR2^−^, CD25^−^TNFR2^+^, and CD25^−^TNFR2^−^, to identify their respective ability to inhibit proliferation of target CD4^+^ Teffs, the results identified that both CD8^+^CD25^+^ and CD8^+^CD25^−^ cells were more potent inhibitors of proliferation if they coexpressed TNFR2, suggesting that TNFR2 is a more important marker than CD25 on CD8^+^Foxp3^+^ Tregs ([@B17]). Additionally, *in vitro*-induced CD8^+^Foxp3^+^ Tregs expressed both TNFR2 and PDL-1. When sorting CD8^+^ T cells into TNFR2^+^PDL-1^+^, TNFR2^+^PDL-1^−^, TNFR2^−^PDL-1^+^, or TNFR2^−^PDL-1^−^, it was observed that TNFR2-PDL-1 double positive cells exhibited much stronger suppressive activity than control sham sorted cells. TNFR2 or PDL-1 single positive cells had modest suppressive activity, while the double negative cells had none ([@B24]). Once more, these data emphasized that TNFR2 might be a characteristic expression marker for functional CD8^+^Foxp3^+^ Tregs and the coexpression of TNFR2 and PDL-1 on CD8^+^Foxp3^+^ Tregs may represent cells with stronger suppressive activity.

TNF/TNFR2 Interaction Delivers a Co-Stimulatory Signal to Induce Foxp3 by CD8^+^Foxp3^+^ Tregs {#S2-2}
----------------------------------------------------------------------------------------------

It was shown that Foxp3 appears to function as a master regulator of the regulatory pathway in the development and function of Tregs ([@B41]--[@B43]). Interestingly, the TNF/TNFR2 interaction on the surface of CD8^+^ T cells could promote the induction of Foxp3 in the presence of anti-CD3/CD28 beads to generate more CD8^+^Foxp3^+^ Tregs. Previous studies have shown that when PBMCs from rheumatoid arthritis (RA) patients were cultured with anti-CD3 for 24 h, a greater percentage of CD8^+^Foxp3^+^ Tregs were generated and expressed high levels of CD25 and TNFR2 ([@B44]). However, when anti-TNF monoclonal antibodies (mAb) were added into the *in vitro* culture system, the percentage of Foxp3 expression on CD8^+^ Tregs decreased significantly ([@B44]). Furthermore, experimental results show that membrane TNF/TNFR2 interactions, in combination with CD80/CD28 interactions between monocytes and CD8^+^ T cells from RA patients, could also promote the induction of CD8^+^Foxp3^+^ Tregs *in vitro*, while combined CD86 and TNF blockade completely ablated the process ([@B44]). These data all indicated that the effect mediated by TNFR2 expression on CD8^+^ T cells played a prominent role for the generation of CD8^+^Foxp3^+^ Tregs in the presence of anti-CD3 *in vitro*. However, a defined mechanism remains elusive and the corresponding process *in vivo* remains to be studied.

TNF/TNFR2 Interactions Mediate the Suppressive Activity of CD8^+^Foxp3^+^ Tregs {#S2-3}
-------------------------------------------------------------------------------

Tumor necrosis factor was also found to be responsible for the induction of CD8^+^Foxp3^+^ Tregs, as anti-TNF monoclonal antibodies (mAb) could dramatically abrogate the proliferation of CD8^+^Foxp3^+^ Tregs, prevent the upregulation of CD25 in response to anti-CD3 *in vitro* on CD8^+^ Tregs, and interfere with the suppressive activity of CD8^+^Foxp3^+^ Tregs. Furthermore, TNFR2 expression was upregulated significantly after CD8^+^Foxp3^+^ Tregs were stimulated with anti-CD3 mAb *in vitro*, whereas the TNFR1 level was relatively low ([@B17]), indicating that the effect of TNF was more potent *via* TNFR2 to mediate the downstream signal. Additionally, TNF could upregulate PDL-1 expression on CD8^+^Foxp3^+^ Tregs *via* TNFR2 and which was greatly decreased by blocking with soluble TNF receptors (TNFR2-Fc) ([@B17]). Therefore, upregulating PDL-1 expressing on CD8^+^ Tregs might be a specific mechanism for TNF/TNFR2 mediating CD8^+^ Treg suppressive activation ([@B45]). Compared with TNFR2 expressed on CD4^+^ Tregs, little is known about the significance of TNFR2 on CD8^+^ Tregs. The available evidence indicates that TNFR2 expression on CD8^+^Foxp3^+^ Tregs is beneficial for their function, and defects in their suppressive function occurred when TNFR2 was neutralized. CD8^+^ Tregs have been shown to exhibit different phenotypes in different diseases, including viral infection ([@B46]), autoimmune diseases ([@B47]), graft-versus-host disease (GVHD) ([@B48], [@B49]), and cancer ([@B44], [@B50]). However, it is unclear whether TNFR2 can be used as a suppressive marker for all the reported CD8^+^ Treg subsets.

TNFR2 Expressed on CD8^+^ Effector T Cells {#S3}
==========================================

Studies on TNFR2 expressed on CD8^+^ Teffs are relatively more sufficient than studies on TNFR2 expressed on CD8^+^ Tregs (Figure [2](#F2){ref-type="fig"}). Numerous reports have shown that CD8^+^ Teffs are critical players involved in various immune responses ([@B51]--[@B53]). Efficient induction of CD8^+^ Teffs requires coordinated signaling through a number of pathways, including T cell receptor (TCR) ligation with peptide in the context of major histocompatibility complex class I (MHC I), costimulatory molecules, and cytokines([@B53]). TNFR2, but not TNFR1, has been previously shown to be the predominant TNF receptor on activation CD8^+^ Teffs ([@B54], [@B55]). Thus, the direct effects of TNF on CD8^+^ Teffs are mainly mediated through TNFR2 ([@B54], [@B55]). Typically, T-cell-mediated immune responses can be divided into three parts: (1) antigen recognition; (2) proliferation and differentiation; and (3) activation-induced cell death (AICD). Once an activation signal has been received, primary CD8^+^ T cells undergo proliferation, expansion, and differentiation. It has been reported that TNFR2 expression was involved in CD8^+^ Teffs activation in certain phases of an immune response. For instance, it has been found that TNFR2 not only lowered the threshold for T cell activation, but also provided early costimulatory signals during T cell activation ([@B56]--[@B58]). Additionally, TNFR2 also plays a critical role in regulating AICD in activated CD8^+^ Teffs ([@B59]).

![Tumor necrosis factor (TNF) receptor type II (TNFR2) modulates the process of immune response mediated by CD8^+^ effector T cells (Teffs). In the early phase of immune response, TNFR2 is a CD8^+^ Teff costimulatory molecule for IL-2, survivin, Bcl-2, and Bcl-x~L~ induction to promote CD8^+^ Teffs survival, proliferation, and activation and involve in controlling the cell fate during TCR/CD28-mediated stimulation. TNFR2 is essential for the production of IFN-γ and TNF-α in CD8^+^ Teffs to promote antigen clearance. Additionally, TNFR2 is also required for CD8^+^ Teffs to upregulate Fas-L and granzyme B to enhance their cytotoxic activity. However, in the anaphase of immune response, TNFR2 can induce activated CD8^+^ T cells programmed cell death to terminate the immune response *via* the degradation of a pro-survival signal---TRAF2, which is required for the recruitment of cellular inhibitor of apoptosis proteins cIAP-1 and cIAP-2 to the TNFR2 signaling complex and activates nuclear factor-κB.](fimmu-09-00583-g002){#F2}

TNFR2 as an Activator Molecule in the Early Phase of Immune Response {#S3-1}
--------------------------------------------------------------------

### TNFR2 Is Required for Primary CD8^+^ T Cell Survival and Proliferation {#S3-1-1}

CD28 is a key costimulatory molecule for IL-2 induction, based on its ability to substantially augment expression in T cells stimulated *via* the TCR ([@B60]). However, the effects mediated by CD28 were found to be insufficient to sustain long-term T cell survival ([@B61]). Nevertheless, TNFR2 plays a critical role in promoting activation and survival of naive T cells during a primary response ([@B5], [@B62]). CD8^+^ T cells deficient in TNFR2 possessed a marked defect in IL-2 production, a critical T cell growth factor ([@B63], [@B64]), resulting in a decreased proliferative response ([@B57]), suggesting that TNFR2 is a CD8^+^ T cell costimulatory molecule involved in controlling the cell fate during TCR/CD28-mediated stimulation ([@B57]). Additionally, TNFR2 deficiency in CD8^+^ T cells increased the requirements for a TCR agonist, approximately fivefold to achieve a proliferative response equivalent to wild-type CD8^+^ T cells in several infection models ([@B5], [@B56]--[@B58]). Additionally, in a mouse tumor model, the proportion of proliferating transgenic tumor-specific CD8^+^ T cells in TNFR2 deficient mice were significant reduced in tumor-draining lymph nodes ([@B54]). These data indicated that TNFR2 sustained the early proliferative phase during CD8^+^ T cell cells activation. Moreover, during CD8^+^ T cell activation in response to antigen *in vitro*, TNFR2 deficiency was related to a reduction of anti-apoptotic molecules, such as survivin, Bcl-2, and Bcl-x~L~ ([@B57], [@B58]), indicating the critical roles of TNFR2 in CD8^+^ T cell survival.

### TNFR2 Is Required for the Secretion of Effector Molecules by CD8^+^ Teffs {#S3-1-2}

One of the key effector functions of activated CD8^+^ T cells is the ability to produce antiviral and pro-inflammatory cytokines, including interferon (IFN)-γ and TNF-α ([@B65]). Typically, cytokine production by antiviral CD8^+^ T cells occurs in a hierarchical fashion, with the majority producing IFN-γ, and a subset of those producing TNF-α ([@B66]--[@B68]). During infection, such as respiratory influenza or *C. muridarum* infection, the production of IFN-γ was significantly decreased in TNFR2^−/−^CD8^+^ T cell, with significantly delayed antigen clearance in TNFR2^−/−^ mice ([@B69], [@B70]). These results suggest that TNFR2 primarily promotes the activation of CD8^+^ T cells and enhances the ability of CD8^+^ T cells to clear antigen. When tumor-special CD8^+^ T cells, isolated from TNFR2^−/−^ mice, TNFR1^−/−^, or wild-type mice, were cultured with specific antigens *in vitro*, IFN-γ levels produced by TNFR2^−/−^CD8^+^ T cells was less than TNFR1^−/−^ or wild-type CD8^+^ T cells ([@B54]), indicating that TNFR2 was also necessary for the optimal production of IFN-γ to clear tumor antigens during the T cell activation phase.

Second, TNF-α is increased during CD8^+^ T cell activation following antigenic stimulation ([@B71], [@B72]). Similar to IFN-γ, TNF-α is critically required for efficient CD8^+^ T cell-mediated responses from initiation to pathogen clearance. However, TNF-α levels produced by CD8^+^ T cells were not always in line with INF-γ production. During colitis, CD8^+^ T cells from TNFR2^−/−^ mice expressed significantly higher levels of TNF-α compared with wild-type mice, which was sufficient to worsen colonic inflammation ([@B73]). Similarly, after intranasal challenge with HKx31 influenza A virus, TNF-α production was also increased in TNFR2^−/−^ mice, compared with wild-type mice ([@B73]). It is possible that the increased TNF-α in TNFR2 deficient mice may be due to a negative feedback loop in the TNF-TNFR2 signaling ([@B5], [@B59], [@B62], [@B73]).

### TNFR2 Is Required for CD8^+^ T Memory Cells Recovery {#S3-1-3}

After encountering with microbial antigen, T cells can differentiate into memory cells to provide long-lasting protection against subsequent pathogens ([@B18], [@B74], [@B75]). During transplantation, microbe-elicited T memory cells can also cross-react with allogeneic antigen and mediate graft rejection, a process termed allogeneic heterologous immunity. TCR affinity is hypothesized to be critically important in the context of allogeneic heterologous immunity ([@B18], [@B76], [@B77]). Notably, TNFR2 plays an important role for low-affinity-primed memory CD8^+^ T cells mediating optimum recall responses. During heterologous rechallenge, low-affinity-primed memory effectors upregulated TNFR2 surface expression to mediated graft rejection, whereas blockade of TNFR2 significantly attenuated graft rejection and prolonged graft survival ([@B18]). These data indicated that TNFR2 is required and critical for memory CD8^+^ T cells recovery in immune responses.

### TNFR2 Is Required for Cytotoxic T Lymphocyte (CTL) Activity {#S3-1-4}

Granzyme B is a serine protease expressed by CTL and together with the pore forming protein, perforin, mediates apoptosis in target cells ([@B78]). Notably, TNFR2 engagement with TNF-α induces the expression of granzyme B in CD8^+^ T cells, when costimulation with CD86 is provided simultaneously. TNFR2 was also shown to be upregulated on granzyme B^+^CD8^+^ T cells in aging mice and humans ([@B79]), indicating that the TNF/TNFR2 signaling pathway in CD8^+^ T cell could reinforce the cells' cytotoxic activity to induce target cells apoptosis *via* the release of granzyme B.

A second way for CTL to induce apoptosis is *via* cell-surface Fas--Fas ligand (FasL) interactions between CTL and infected cells. FasL is expressed predominantly on activated lymphocytes and is able to induce programmed cell death in most Fas-expressing cells ([@B80], [@B81]). The number of FasL-expressing CD8^+^ intrahepatic lymphocytes isolated from various strains of hepatic adenovirus-infected TNFR2^−/−^ mice were found to be significantly reduced compared with wild-type mice ([@B82]). Furthermore, TNFR2^−/−^ intrahepatic lymphocytes were significantly less efficient in killing adenovirus-infected hepatocyte target cells than intrahepatic lymphocytes obtained from adenovirus-infected wild-type mice ([@B82]). These data provide evidence suggesting that TNFR2 can potentiate FasL-mediated cytotoxicity for CD8^+^ Teffs.

TNFR2 Is as an Apoptosis Signal on Activated CD8^+^ Teffs {#S3-2}
---------------------------------------------------------

Tumor necrosis factor receptor type II is essential for both optimal proliferation during CD8^+^ T cell activation and for the induction of AICD that terminates the proliferative response ([@B59]). Previous study had shown that TNFR2^−/−^CD8^+^ T cells exhibited consistently high resistance to AICD, leading to worsen colonic inflammation ([@B73]), indicating that TNFR2 is a critical negative regulator of activated CD8^+^ T cells by promoting AICD to terminate the immune response. Moreover, TNFR2 signaling was reported to lead to the degradation of TNF receptor-associated factor 2 (TRAF2) ([@B83]), which were important in the regulation of the receptor signaling ([@B83]--[@B86]). Notably, TRAF2 is known as a pro-survival signal ([@B87]), which is required for the recruitment of cellular inhibitor of apoptosis proteins (cIAP)-1 and -2 to the TNFR2 signaling complex ([@B88]) and activates nuclear factor (NF)-κB to mediate its anti-apoptotic effects ([@B89]--[@B91]). The overexpression of TRAF2 in wild-type CD8^+^ T cells did not affect the percentage of apoptotic cells, whereas the silencing of TRAF2 in activated TNFR2^−/−^CD8^+^ T cells could render them as sensitive to AICD as activated wild-type CD8^+^ T cells ([@B59]). Collectively, these results provide evidence that the TNFR2 signaling pathway is involved in regulating AICD and that TRAF2 depletion induced by TNFR2 is critical to this process.

Conclusion {#S4}
==========

Tumor necrosis factor receptor type II is an attractive molecular marker to identify both CD8^+^Foxp3^+^ Tregs and CD8^+^ Teffs. For CD8^+^Foxp3^+^ Tregs, TNFR2 is necessary for the induction of Foxp3 and regarded as a functional marker of their suppressive ability. For CD8^+^ Teffs, TNFR2 serves as an activator for proliferation and cytotoxic ability in the early stage of an immune response and as an apoptosis signal for activated CD8^+^ Teffs to terminate the immune response. Both CD8^+^Foxp3^+^ Tregs and CD8^+^ Teffs could express high levels of TNFR2 and were involved in various diseases. It is noteworthy that there is an antagonistic relationship between CD8^+^ Tregs and CD8^+^ Teffs. The TNF-TNFR2 signaling pathway potentially activates both of them, so targeting TNFR2 may impair the function of protective Tregs or Teffs as a side effect in the treatment of diseases ([@B4]). Furthermore, studies have shown that TNFR2 is a potential therapeutic target with remarkable success in cancer immunotherapy. A TNFR2 antagonists could specifically inhibit CD4^+^Foxp3^+^ Tregs expansion in the tumor microenvironment, whereas it had little inhibitory effects on CD4^+^ Tregs in periphery or from healthy donors, and killed human ovarian tumor cells directly. However, little is known about TNFR2 agonists or antagonists aimed at altering TNFR2 expression on tumor-associated CD8^+^ Tregs and CD8^+^ Teffs. Further understanding of TNFR2 expression on CD8^+^ T cells and the pathways that are active and important in different disease-related microenvironments will provide better understanding of its impacts on TNF-mediated pathology, and may help in the development of more effective targeted therapeutics.

Furthermore, recent evidence indicated that the relationship between TNF/TNFR2 and T cell responses is complex and, at times, paradoxical. There is controversy to the specific effects of TNF on different T cell subsets ([@B92]). The explanation for such contradictory outcomes may lay in how downstream signaling pathways are activated and drive disease ([@B92]). Consequently, a precise understanding of the level and/or ratio of TNFR2 expressed on different T cell subsets will help in the use of TNFR2 agonists or antagonists as therapies.
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